About
Seasoned businessmen, Lyme disease sufferers and scientists out of frustration and concern about the performance of current tests created Veramarx, Inc. The company has shown that its cutting-edge molecular Lyme Veramarx™ (a molecular bio-signature) results in an accurate test for Lyme disease. This opportunity is growing into a multi-billion dollar market. The disease must be identified early and accurately to be optimally treated and current tests do not perform well, 50% of the cases are missed and this leads to unnecessary suffering and expense. In April of 2014, the company successfully completed its second milestone that proved our principal hypothesis that a specific Lyme Veramarx™ molecular bio-signature existed and could diagnose Lyme disease. Most importantly, when this exact algorithm was used in validation testing it had an AUC, a measure of accuracy, of 94%. This exceeds the accuracy needed for broadly accepted and utilized clinical tests. Commercialization in 2015.